1. Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment
- Author
-
Hatae, Ryusuke, Kyewalabye, Keith, Yamamichi, Akane, Chen, Tiffany, Phyu, Su, Chuntova, Pavlina, Nejo, Takahide, Levine, Lauren S, Spitzer, Matthew H, and Okada, Hideho
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Cancer ,Brain Cancer ,Rare Diseases ,Brain Disorders ,Neurosciences ,Mice ,Humans ,Animals ,Tumor Microenvironment ,AMP-Activated Protein Kinases ,Xenograft Model Antitumor Assays ,Cell Line ,Tumor ,Brain ,Glioma ,T-Lymphocytes ,TOR Serine-Threonine Kinases ,Brain cancer ,Cancer immunotherapy ,Hypoxia ,Otology ,Biomedical and clinical sciences ,Health sciences - Abstract
The efficacy of chimeric antigen receptor T cell (CAR-T) therapy has been limited against brain tumors to date. CAR-T cells infiltrating syngeneic intracerebral SB28 EGFRvIII gliomas revealed impaired mitochondrial ATP production and a markedly hypoxic status compared with ones migrating to subcutaneous tumors. Drug screenings to improve metabolic states of T cells under hypoxic conditions led us to evaluate the combination of the AMPK activator metformin and the mTOR inhibitor rapamycin (Met+Rap). Met+Rap-pretreated mouse CAR-T cells showed activated PPAR-γ coactivator 1α (PGC-1α) through mTOR inhibition and AMPK activation, and a higher level of mitochondrial spare respiratory capacity than those pretreated with individual drugs or without pretreatment. Moreover, Met+Rap-pretreated CAR-T cells demonstrated persistent and effective antiglioma cytotoxic activities in the hypoxic condition. Furthermore, a single intravenous infusion of Met+Rap-pretreated CAR-T cells significantly extended the survival of mice bearing intracerebral SB28 EGFRvIII gliomas. Mass cytometric analyses highlighted increased glioma-infiltrating CAR-T cells in the Met+Rap group, with fewer Ly6c+CD11b+ monocytic myeloid-derived suppressor cells in the tumors. Finally, human CAR-T cells pretreated with Met+Rap recapitulated the observations with murine CAR-T cells, demonstrating improved functions under in vitro hypoxic conditions. These findings advocate for translational and clinical exploration of Met+Rap-pretreated CAR-T cells in human trials.
- Published
- 2024